Insider Buying: Biodesix (NASDAQ:BDSX) Director Acquires 142,045 Shares of Stock

Biodesix, Inc. (NASDAQ:BDSX) Director Jack Schuler bought 142,045 shares of the company’s stock in a transaction that occurred on Friday, September 19th. The shares were bought at an average cost of $7.04 per share, for a total transaction of $999,996.80. Following the transaction, the director directly owned 1,380,745 shares of the company’s stock, valued at $9,720,444.80. This trade represents a 11.47% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Biodesix Stock Down 4.5%

Shares of BDSX opened at $8.01 on Friday. The company has a debt-to-equity ratio of 41.11, a quick ratio of 2.14 and a current ratio of 2.14. The company has a 50-day simple moving average of $8.13 and a 200-day simple moving average of $8.68. Biodesix, Inc. has a 52 week low of $3.44 and a 52 week high of $36.00. The firm has a market capitalization of $58.71 million, a P/E ratio of -1.38 and a beta of 1.00.

Biodesix (NASDAQ:BDSX) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.40) by ($0.20). The firm had revenue of $20.02 million for the quarter, compared to the consensus estimate of $18.47 million. Biodesix had a negative net margin of 53.66% and a negative return on equity of 269.67%. Biodesix has set its FY 2025 guidance at EPS. On average, equities research analysts expect that Biodesix, Inc. will post -0.35 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the stock. Canaccord Genuity Group set a $20.00 price target on shares of Biodesix and gave the stock a “buy” rating in a research note on Friday, September 19th. Wall Street Zen upgraded shares of Biodesix to a “sell” rating in a research report on Saturday, September 13th. Four equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, Biodesix currently has a consensus rating of “Moderate Buy” and an average price target of $32.50.

Institutional Investors Weigh In On Biodesix

Large investors have recently made changes to their positions in the company. Jane Street Group LLC acquired a new stake in shares of Biodesix during the 4th quarter worth about $119,000. XTX Topco Ltd bought a new stake in Biodesix during the first quarter worth about $64,000. Blair William & Co. IL increased its holdings in shares of Biodesix by 33.3% during the first quarter. Blair William & Co. IL now owns 124,100 shares of the company’s stock worth $78,000 after buying an additional 31,000 shares in the last quarter. Northern Trust Corp raised its stake in shares of Biodesix by 286.5% in the fourth quarter. Northern Trust Corp now owns 169,132 shares of the company’s stock valued at $259,000 after acquiring an additional 125,368 shares during the last quarter. Finally, Millennium Management LLC boosted its holdings in shares of Biodesix by 20.2% in the 4th quarter. Millennium Management LLC now owns 198,671 shares of the company’s stock worth $304,000 after acquiring an additional 33,329 shares in the last quarter. Institutional investors own 20.96% of the company’s stock.

Biodesix Company Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.